Vertex Pharmaceuticals, a global biotechnology company, agreed to acquire Alpine Immune Sciences, a clinical-stage biopharmaceutical company, for $4.9bn. “Alpine is a compelling strategic fit for Vertex and furthers our ambition of using scientific innovation to create transformative medicines targeting serious diseases with high unmet need in specialty markets. We look forward to welcoming the talented Alpine team to Vertex and believe that together we can bring povetacicept, a potential best-in-class treatment for IgAN to patients faster. We also look forward to fully exploring povetacicept’s potential as a ‘pipeline-in-a-product' and adding Alpine’s protein engineering and immunotherapy capabilities to Vertex’s toolbox,” Reshma Kewalraman, Vertex CEO and President.